Lithium has been widely used for the treatment of bipolar disorder. But lithium has a narrow therapeutic index and it can cause side effects such as thirst, weight gain, tremor, polyuria and memory problems. Although the mechanism for lithium action in treatment of bipolar disorder is still not fully understood, inhibition of inositol monophosphatase (IMPase) and the subsequent depletion of the inositol pool in living cells have been implicated as the primary therapeutic benefit of lithium therapy. Therefore, a selective IMPase inhibitor with reduced side effects might be a good drug candidate to replace lithium for the treatment of bipolar disorder. Several IMPase inhibitors have been discovered previously. However, they are not suitable for therapeutic use because of their poor cell membrane penetrability or oral bioavailability; the development of new cell-permeable IMPase inhibitors is needed. IMPase catalyzes the hydrolysis of inositol-1-phosphate (IP1) to release free inositol. Binding of an agonist to a Gq coupled GPCR results in the activation of PLC, which hydrolyzes the PIP2 to form inositol-1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). While DAG activates protein kinase C (PKC), IP3 triggers the elevation of intracellular free Ca2+. The IP3 is very rapidly inactivated by hydrolysis to IP2, IP1 and then inositol by a series of enzymes including IMPase. Free inositols are used for synthesis of PI and thus start another inositol cycle. To identify new cell-permeable IMPase inhibitors, we developed a cell-based IMPase assay in which the cytosolic IP1 is measured by a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. In this assay, an IP1 specific antibody is used to detect the labeled IP1 tracer. When the cell lysate contains the elevated IP1 due to the inhibition of IMPase, the TR-FRET between the labeled antibody and IP1 tracer is disrupted resulting in a reduction in the total signal. Since the TR-FRET is used, this cell-based assay is a homogenous assay without cell wash and medium change that is suitable for assay miniaturization and HTS. In this particular assay, a small amount of lithium is added to potentiate the response of weak activators. A Chinese hamster ovary (CHO) cell line stably expressing the M1 receptor (CHO-M1) was obtained from ATCC and maintained in F-12 Kaighn's media (Invitrogen, Carlsbad, CA) supplemented with 10 % FBS, 100 units/ml penicillin, 100 ug/ml streptomycin and 250 ug/ml geneticin at 37C, 5% CO2 in a humidified atmosphere. Before the assay, aliquots of cells were frozen and stored at -135C. The assay was performed in 1536-well format. Data are reported for both the ratio of the two emission wavelengths, and also for the component 'donor' channel, Em2=620. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (18.4 mM LiCl). AC50 values were determined from concentration-response data modeled with the standard Hill equation. (1) Frozen CHO-M1 cells were thaw, washed once with fresh media and resuspended in F12K media containing 10% FBS, 100 units/ml penicillin and 100 ug/ml streptomycin. Cells were plated at 4ul/well (2000 cells) in white, tissue culture treated 1536-well plates, and then cultured at 37C, 5 % CO2 for 16 to 30 hours. (2) Add 23 nl/well of compound in DMSO solution. The final titration for each compound was between 0.6 nM and 46 uM. (3) Add 1 ul of stimulation reagent (250 uM carbachol and 500 uM LiCl in stimulation buffer containing10mM HEPES, 1mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 50mM LiCl, pH 7.4) (4) Incubation at 37C, 5 % CO2 for 30 min. (5) Add 1 ul/well of d2-conjugated IP1 (d2-IP1) and 1 ul/well of Eu+ cryptate conjugated anti-IP1 antibody (Eu+-Ab) prepared in the cell lysis buffer, both from the IP-One kit (Cisbio, MA). (6) Incubate at room temperature for 10 minutes. (7) Detect the assay plate (Ex = 320, Em1 =665 and Em2 620) in a ViewLux plate reader.
bao:BAO_0000812 "2301" ; # "has summary assay" -> "2301"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000295 ; # "has participant" -> "phosphatase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000212 bao:BAO_0000129 ; # "has assay method" -> "immunoassay"
bao:BAO_0000207 bao:BAO_0000004 ; # "has detection method" -> "time resolved fluorescence resonance energy transfer"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "IMPase Inhibitors" ; # "screening campaign name" -> "IMPase Inhibitors"
bao:BAO_0002853 "qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium" ; # "has assay title" -> "qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "37 degree celsius" ; # "has temperature value" -> "37 degree celsius"
bao:BAO_0002833 "30 minute" ; # "has incubation time value" -> "30 minute"
bao:BA0_0090012 "Lithium Chloride (LiCl 18.4 millimolar)" ; # "has participant" -> "Lithium Chloride (LiCl 18.4 millimolar)"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BAO_0000740 bao:BAO_0000118 ; # "has assay control" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000334 ; # "has assay control" -> "background control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Wei Zheng" ; # "material entity assay provider" -> "Wei Zheng" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BAO_0002739 "\"D2-labeled IP1, HTRF acceptor fluorophore D2\"" ; # "has substrate" -> ""D2-labeled IP1, HTRF acceptor fluorophore D2"" || bao:BAO_0003102 bao:BAO_0002030 ; # "has role" -> "coupled substrate"
bao:BAO_0002000 bao:BAO_0000957 ; # "has measured entity" -> "Lithium chloride" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35222> ; # "has role" -> "inhibitor"
bao:BAO_0002000 bao:BAO_0000876 ; # "has measured entity" -> "Carbachol" || bao:BAO_0003102 bao:BAO_00020138 ; # "has role" -> "potentiator"
bao:BA0_0090012 "Inositol monophosphatase 1" ; # "has participant" -> "Inositol monophosphatase 1"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0002421> ; # "has cell line" -> "CHO cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_10116> ; # "has organism" -> "Rattus norvegicus"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P97697" ; # "uniprot ID" -> "P97697"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10116" ; # "NCBI taxonomy ID" -> "10116"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% fetal bovine serum" ; # "material entity culture serum" -> "10% fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"F12 Kaighn's with 10 % FBS, 100 units/ml penicillin, 100 microg/ml streptomycin and 250 microg/ml geneticin\"" ; # "material entity culture medium" -> ""F12 Kaighn's with 10 % FBS, 100 units/ml penicillin, 100 microg/ml streptomycin and 250 microg/ml geneticin"" || bao:BAO_0003102 bao:BAO_0000114 ; # "has role" -> "culture medium"
bao:BAO_0002922 "IP-One kit (Cisbio) buffers" ; # "has assay medium" -> "IP-One kit (Cisbio) buffers"
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing the muscarinic M1 receptor" ; # "DNA construct" -> "Expressing the muscarinic M1 receptor"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0000502 "\"Europium Eu3+ cryptate-labeled anti-IP1, HTRF fluorophore donor, Cisbio\"" ; # "antibody" -> ""Europium Eu3+ cryptate-labeled anti-IP1, HTRF fluorophore donor, Cisbio""
bao:BA0_0090012 bao:BAO_0000886 ; # "has participant" -> "Inositol-1-phosphate"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000948 ; # "has assay kit" -> "IP-One HTRF Assay"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000881 ; # "has manufacturer" -> "Cisbio" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000691 ; # "uses detection instrument" -> "ViewLux ultraHTS Microplate Imager"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "320 nanometer" ; # "has excitation wavelength value" -> "320 nanometer"
bao:BAO_0002918 "620 nanometer" ; # "has emission wavelength value" -> "620 nanometer"
bao:BAO_0002918 "665 nanometer" ; # "has emission wavelength value" -> "665 nanometer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "8" ; # "has concentration-point number" -> "8"
bao:BAO_0000196 bao:BAO_0000441 ; # "has mode of action" -> "competitive binding"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
